Bristol-Myers Squibb adds data to ORENCIA labelling

Bristol-Myers Squibb has announced that it has updated its labelling for ORENCIA (abatacept) to incorporate details for earlier use in patients with moderate to severe rheumatoid arthritis.

The efficacy and safety data added offers further guidance for the use of the product and was validated by the Food and Drug Administration following an Abatacept study to gauge remission and joint damage progression in methotrexate-naive patients with moderate to severe rheumatoid arthritis.

Lead investigator of the study Rene Westhovens stated: “Earlier treatment with a biologic such as ORENCIA, in combination with methotrexate in patients with poor prognostic factors, may help some patients get back to daily activities so often limited by this debilitating disease.”

Earlier this week, Bristol-Myers Squibb revealed that a court has granted it preliminary approval for the settlement of its shareholder case, Sampson vs Robinson.